The estimated Net Worth of V Luxco S.A R.L.Versant Ven... is at least $1.07 Milion dollars as of 7 October 2019. V Ven owns over 333,333 units of Aprea Therapeutics stock worth over $1,073,332 and over the last 5 years V sold APRE stock worth over $0.
V has made over 1 trades of the Aprea Therapeutics stock since 2019, according to the Form 4 filled with the SEC. Most recently V bought 333,333 units of APRE stock worth $4,999,995 on 7 October 2019.
The largest trade V's ever made was buying 333,333 units of Aprea Therapeutics stock on 7 October 2019 worth over $4,999,995. On average, V trades about 333,333 units every 0 days since 2019. As of 7 October 2019 V still owns at least 333,333 units of Aprea Therapeutics stock.
You can see the complete history of V Ven stock trades at the bottom of the page.
Over the last 5 years, insiders at Aprea Therapeutics have traded over $63,126,246 worth of Aprea Therapeutics stock and bought 2,073,560 units worth $29,606,912 . The most active insiders traders include Group, Llc Green Jeremy Red..., Vantage I, L.P.Versant Vant... a John B Iii Henneman. On average, Aprea Therapeutics executives and independent directors trade stock every 43 days with the average trade being worth of $420,918. The most recent stock trade was executed by John P. Hamill on 13 March 2024, trading 1,010 units of APRE stock currently worth $7,363.
Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel cancer therapeutics that target DNA damage response pathways. Its lead product candidate is ATRN-119, an oral ATR inhibitor that is in phase 1/2a clinical trial to treat patients with advanced solid tumors. The company's products pipeline also includes ATRN-Backup, an ATR inhibitor; ATRN-W1051 to treat anti-tumor activity; and ATRN-DDRi. Aprea Therapeutics, Inc. is based in Boston, Massachusetts.
Aprea Therapeutics executives and other stock owners filed with the SEC include: